{"protocolSection":{"identificationModule":{"nctId":"NCT00006518","nctIdAliases":["NCT00898651"],"orgStudyIdInfo":{"id":"010038"},"secondaryIdInfos":[{"id":"01-C-0038"}],"organization":{"fullName":"National Institutes of Health Clinical Center (CC)","class":"NIH"},"briefTitle":"Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer","officialTitle":"Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer"},"statusModule":{"statusVerifiedDate":"2024-08-22","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2000-12-06","type":"ACTUAL"},"studyFirstSubmitDate":"2000-11-22","studyFirstSubmitQcDate":"2000-11-22","studyFirstPostDateStruct":{"date":"2000-11-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-08-23","lastUpdatePostDateStruct":{"date":"2024-08-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"National Cancer Institute (NCI)","class":"NIH"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"BACKGROUND:\n\n* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer.\n* This protocol provides a mechanism to affect a variety of such studies.\n\nOBJECTIVES:\n\n-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.\n\nELIGIBILITY:\n\n-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.\n\nDESIGN:\n\n* Up to 999 subjects will be enrolled in this study.\n* Blood samples may be collected at the initial visit, and at follow-up visits.\n* Other fluids/excretions may be collected (such as urine, saliva, semen, and stool).\n* Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants.\n* Specific risks will be described in a separate consent to be obtained at the time of the biopsy.\n* Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators.","detailedDescription":"BACKGROUND:\n\n* A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus (KSHV), infection with other oncogenic viruses, or cancer.\n* This protocol provides a mechanism to affect a variety of such studies.\n\nOBJECTIVES:\n\n-Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.\n\nELIGIBILITY:\n\n-Eligibility criteria include age 18 years or older and at least one of the following: Exposure risk to HIV, KSHV, or HPV; HIV seropositive; KSHV seropositive; EBV seropositive; HTLV-1 seropositive; malignancy, Castleman s disease, or skin lesions with appearance of Kaposi s sarcoma; or cervical or anal intraepithelial lesion.\n\nDESIGN:\n\n* Up to 999 subjects will be enrolled in this study.\n* Blood samples may be collected at the initial visit, and at follow-up visits.\n* Other fluids/excretions may be collected (such as urine, saliva, semen, and stool).\n* Tumor samples may be obtained by fine needle aspirate, by removal of pleural or peritoneal fluid, by skin punch biopsy, or by excisional biopsy, providing the tumor is accessible with minimal risk to the participants.\n* Specific risks will be described in a separate consent to be obtained at the time of the biopsy.\n* Samples will be studied in the HIV and AIDS Malignancy Branch, CCR, NCI; laboratories in NCI-Frederick; or those of collaborating investigators."},"conditionsModule":{"conditions":["HIV","Kaposi's Sarcoma","Lymphomas","Multicentric Castleman's Disease","Primary Effusion Lymphoma"],"keywords":["Tumor","Viruses","HIV","KSHV","AIDS","Natural History"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":999,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"1","description":"Participants with HIV infection, KSHV infection, or with cancer"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Acquisition of serum, circulating cells, bone marrow, and tumor or normal tissue samples from participants with HIV infection, KSHV infection, or with cancer.","description":"Proportion of participants that have contributed serum, circulating cells, bone marrow, and tumor or normal tissue samples","timeFrame":"Ongoing"}]},"eligibilityModule":{"eligibilityCriteria":"* INCLUSION CRITERIA:\n* Age 18 years or older.\n* ECOG performance status less than or equal to 3.\n\nAt least one of the following:\n\n* Exposure risk to HIV, KSHV, or HPV\n* HIV seropositive\n* KSHV seropositive\n* EBV seropositiv\n* HTLV-1 seropositive\n\nNOTE: infection with HIV, KSHV, EBV, and HTLV-1 are life-long, so if patients have previously been seropositive or have had a disease associated with KSHV (KS, primary effusion lymphoma \\[PEL\\], or KSHV-multicentric Castleman s disease), this is sufficient to meet this criterion for eligibility.\n\n* Malignancy, Castleman's disease, or skin lesions with appearance of Kaposi's sarcoma\n* Cervical or anal intraepithelial lesion\n* Ability of subject to understand and the willingness to sign a written informed consent document. Participants could have a witness signature if they are either blind or illiterate, etc.\n\nEXCLUSION CRITERIA:\n\nInability to provide informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Primary Clinical","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Anaida Widell","role":"CONTACT","phone":"(240) 760-6074","email":"anaida.widell@nih.gov"},{"name":"Robert Yarchoan, M.D.","role":"CONTACT","phone":"(240) 760-6075","email":"robert.yarchoan@nih.gov"}],"overallOfficials":[{"name":"Robert Yarchoan, M.D.","affiliation":"National Cancer Institute (NCI)","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"National Institutes of Health Clinical Center","status":"RECRUITING","city":"Bethesda","state":"Maryland","zip":"20892","country":"United States","geoPoint":{"lat":38.98067,"lon":-77.10026}}]},"referencesModule":{"references":[{"pmid":"8652592","type":"BACKGROUND","citation":"Davis DA, Dorsey K, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry. 1996 Feb 20;35(7):2482-8. doi: 10.1021/bi951525k."},{"pmid":"10677347","type":"BACKGROUND","citation":"Davis DA, Newcomb FM, Moskovitz J, Wingfield PT, Stahl SJ, Kaufman J, Fales HM, Levine RL, Yarchoan R. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. Biochem J. 2000 Mar 1;346 Pt 2(Pt 2):305-11."},{"pmid":"10546852","type":"BACKGROUND","citation":"Pinto LA, Berzofsky JA, Fowke KR, Little RF, Merced-Galindez F, Humphrey R, Ahlers J, Dunlop N, Cohen RB, Steinberg SM, Nara P, Shearer GM, Yarchoan R. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS. 1999 Oct 22;13(15):2003-12. doi: 10.1097/00002030-199910220-00002."}],"seeAlsoLinks":[{"label":"NIH Clinical Center Detailed Web Page","url":"https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2001-C-0038.html"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":".All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP","infoTypes":["STUDY_PROTOCOL","SAP","ICF"],"timeFrame":"Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.","accessCriteria":"Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@Genomic data are made available via dbGaP through requests to the data custodians."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-08-28"},"conditionBrowseModule":{"meshes":[{"id":"D000007239","term":"Infections"},{"id":"D000015658","term":"HIV Infections"},{"id":"D000012514","term":"Sarcoma, Kaposi"},{"id":"D000014777","term":"Virus Diseases"},{"id":"D000008223","term":"Lymphoma"},{"id":"D000054685","term":"Lymphoma, Primary Effusion"},{"id":"D000005871","term":"Castleman Disease"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"},{"id":"D000012509","term":"Sarcoma"},{"id":"D000018204","term":"Neoplasms, Connective and Soft Tissue"},{"id":"D000086982","term":"Blood-Borne Infections"},{"id":"D000003141","term":"Communicable Diseases"},{"id":"D000015229","term":"Sexually Transmitted Diseases, Viral"},{"id":"D000012749","term":"Sexually Transmitted Diseases"},{"id":"D000016180","term":"Lentivirus Infections"},{"id":"D000012192","term":"Retroviridae Infections"},{"id":"D000012327","term":"RNA Virus Infections"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000007153","term":"Immunologic Deficiency Syndromes"},{"id":"D000006566","term":"Herpesviridae Infections"},{"id":"D000004266","term":"DNA Virus Infections"},{"id":"D000009383","term":"Neoplasms, Vascular Tissue"},{"id":"D000016393","term":"Lymphoma, B-Cell"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"}],"browseLeaves":[{"id":"M10283","name":"Infections","asFound":"Infection","relevance":"HIGH"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M14111","name":"Precancerous Conditions","relevance":"LOW"},{"id":"M3522","name":"Acquired Immunodeficiency Syndrome","relevance":"LOW"},{"id":"M18250","name":"HIV Infections","asFound":"HIV Infections","relevance":"HIGH"},{"id":"M15327","name":"Sarcoma","relevance":"LOW"},{"id":"M17522","name":"Virus Diseases","asFound":"Infection, Viral","relevance":"HIGH"},{"id":"M15332","name":"Sarcoma, Kaposi","asFound":"Kaposi's Sarcoma","relevance":"HIGH"},{"id":"M8983","name":"Castleman Disease","asFound":"Castleman Disease","relevance":"HIGH"},{"id":"M27844","name":"Lymphoma, Primary Effusion","asFound":"Primary Effusion Lymphoma","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"M20350","name":"Neoplasms, Connective and Soft Tissue","relevance":"LOW"},{"id":"M2593","name":"Blood-Borne Infections","relevance":"LOW"},{"id":"M15558","name":"Sexually Transmitted Diseases","relevance":"LOW"},{"id":"M17933","name":"Sexually Transmitted Diseases, Viral","relevance":"LOW"},{"id":"M18640","name":"Lentivirus Infections","relevance":"LOW"},{"id":"M15026","name":"Retroviridae Infections","relevance":"LOW"},{"id":"M15149","name":"RNA Virus Infections","relevance":"LOW"},{"id":"M2876","name":"Genital Diseases","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M16355","name":"Syndrome","relevance":"LOW"},{"id":"M10199","name":"Immunologic Deficiency Syndromes","relevance":"LOW"},{"id":"M9643","name":"Herpesviridae Infections","relevance":"LOW"},{"id":"M7442","name":"DNA Virus Infections","relevance":"LOW"},{"id":"M12328","name":"Neoplasms, Vascular Tissue","relevance":"LOW"},{"id":"M18828","name":"Lymphoma, B-Cell","relevance":"LOW"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"T5284","name":"Soft Tissue Sarcoma","relevance":"LOW"},{"id":"T3199","name":"Kaposi Sarcoma","asFound":"Kaposi's Sarcoma","relevance":"HIGH"},{"id":"T991","name":"Castleman Disease","asFound":"Castleman Disease","relevance":"HIGH"},{"id":"T5791","name":"Unicentric Castleman Disease","asFound":"Castleman Disease","relevance":"HIGH"},{"id":"T3921","name":"Multicentric Castleman Disease","asFound":"Multicentric Castleman Disease","relevance":"HIGH"},{"id":"T4690","name":"Primary Effusion Lymphoma","asFound":"Primary Effusion Lymphoma","relevance":"HIGH"},{"id":"T640","name":"B-cell Lymphoma","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC01","name":"Infections"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}